145 related articles for article (PubMed ID: 38634956)
21. Inhibition of glycolysis-driven immunosuppression with a nano-assembly enhances response to immune checkpoint blockade therapy in triple negative breast cancer.
Ren X; Cheng Z; He J; Yao X; Liu Y; Cai K; Li M; Hu Y; Luo Z
Nat Commun; 2023 Nov; 14(1):7021. PubMed ID: 37919262
[TBL] [Abstract][Full Text] [Related]
22. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
[TBL] [Abstract][Full Text] [Related]
23. Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer.
Uzelac B; Krivokuca A; Brankovic-Magic M; Magic Z; Susnjar S; Milovanovic Z; Supic G
Pathol Oncol Res; 2020 Oct; 26(4):2723-2731. PubMed ID: 32681437
[TBL] [Abstract][Full Text] [Related]
24. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
[TBL] [Abstract][Full Text] [Related]
25. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
Wang X; Liu Y
Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
[TBL] [Abstract][Full Text] [Related]
26. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
[TBL] [Abstract][Full Text] [Related]
27. Atezolizumab for the treatment of triple-negative breast cancer.
Heimes AS; Schmidt M
Expert Opin Investig Drugs; 2019 Jan; 28(1):1-5. PubMed ID: 30474425
[TBL] [Abstract][Full Text] [Related]
28. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
29. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
[TBL] [Abstract][Full Text] [Related]
30. TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patients.
Dadiani M; Necula D; Kahana-Edwin S; Oren N; Baram T; Marin I; Morzaev-Sulzbach D; Pavlovski A; Balint-Lahat N; Anafi L; Wiemann S; Korner C; Gal-Yam EN; Avivi C; Kaufman B; Barshack I; Ben-Baruch A
Cancer Immunol Immunother; 2020 Jul; 69(7):1315-1326. PubMed ID: 32198536
[TBL] [Abstract][Full Text] [Related]
31. PD-1/PD-L1 axis importance and tumor microenvironment immune cells.
Lotfinejad P; Kazemi T; Mokhtarzadeh A; Shanehbandi D; Jadidi Niaragh F; Safaei S; Asadi M; Baradaran B
Life Sci; 2020 Oct; 259():118297. PubMed ID: 32822718
[TBL] [Abstract][Full Text] [Related]
32. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
33. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
Anders CK; Abramson V; Tan T; Dent R
Am Soc Clin Oncol Educ Book; 2016; 35():34-42. PubMed ID: 27249684
[TBL] [Abstract][Full Text] [Related]
34. Recent Progress in Triple Negative Breast Cancer Research.
Mouh FZ; Mzibri ME; Slaoui M; Amrani M
Asian Pac J Cancer Prev; 2016; 17(4):1595-608. PubMed ID: 27221827
[TBL] [Abstract][Full Text] [Related]
35. N-Linked glycosylation profiles of therapeutic induced senescent (TIS) triple negative breast cancer cells (TNBC) and their extracellular vesicle (EV) progeny.
Kavanagh EL; Halasz M; Dowling P; Withers J; Lindsay S; Higgins MJ; Irwin JA; Rudd PM; Saldova R; McCann A
Mol Omics; 2021 Feb; 17(1):72-85. PubMed ID: 33325943
[TBL] [Abstract][Full Text] [Related]
36. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
[TBL] [Abstract][Full Text] [Related]
37. Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast Cancer.
Sheng J; Xue X; Jiang K
Curr Mol Med; 2019; 19(2):147-155. PubMed ID: 30854965
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
[TBL] [Abstract][Full Text] [Related]
39. Research advances and new challenges in overcoming triple-negative breast cancer.
Zong Y; Pegram M
Cancer Drug Resist; 2021; 4(3):517-542. PubMed ID: 34888495
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]